Moleculin
Houston, US · Founded 2006 · 22 employees on LinkedIn
Moleculin Biotech is a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses, with a lead program (Annamycin) targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
Founders & leadership
Moleculin was founded in 2006 by Wally Klemp.
Board
MC
Michael ClinardBoard director
RC
Robert ConradBoard director
SD
Stephen DrakeBoard director
JG
J. George GumulkaBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 1 round · 2014
▶$1.4MraisedOct 2014 · 36 investors · Pharmaceuticals
▶$1.4MraisedOct 2014 · 36 investors · Pharmaceuticals
Officers, directors & promoters on the filing
- Walter V KlempExecutive Officer, Director
- Michael ClinardDirector
- Robert ConradDirector
- Stephen DrakeDirector
- J. George GumulkaDirector
- Donald PickerExecutive Officer, Director
- Lori H BissonExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.4M
- Minimum investment
- $5K
- Finders' fees
- $60K
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Texas
- Federal exemptions
- 05
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Moleculin do?
- Moleculin Biotech is a Phase 3 clinical-stage biopharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses, with a lead program (Annamycin) targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.
- Who founded Moleculin?
- Moleculin was founded by Wally Klemp in 2006.
- How much funding has Moleculin raised?
- Moleculin has disclosed $1.4M raised across 1 round.
- Where is Moleculin headquartered?
- Moleculin is headquartered in Houston, US.